Abstract: An anti-tumor agent is provided to a patient to increase a susceptibility of a tumor within the patient to harmonic excitation. Ultrasonic transducers of a wearable are driven to direct a therapeutic ultrasound signal into tissue of the patient. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite and damage the tumor while the anti-tumor agent has increased the susceptibility of the tumor to the harmonic excitation of the therapeutic ultrasound signal.

Abstract: A wearable device includes one or more ultrasonic emitters disposed to direct a therapeutic ultrasound signal into tissue. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite blood clots to liquify the blood clot to become soluble to blood flowing through the head.

Abstract: One or more ultrasonic transducers are driven to direct a therapeutic ultrasound signal into tissue. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite and damage abnormal tissue but not harmonically excite healthy tissue.

Abstract: A health message is received. At least one target brain region is selected in response to receiving the health message. An ultrasound modality profile based on the health message and the at least one target brain region is generated. A wearable therapeutic ultrasound device directs the ultrasound beams to the at least one target brain region in response to the health message. The ultrasound beams are driven with the ultrasound beam profile.

Abstract: Coherent light (e.g., laser light) is emitted into a cranium through an optical fiber. A tissue sample (e.g., red blood cells, blood vessels, brain tissue) within the cranium diffuses the coherent light. Different tissue sample motion quantities generate different coherent light interference patterns. An image of a coherent light interference pattern is captured with an image sensor coupled to an optical element. The speckle contrast of the image quantifies coherent light interference pattern. A waveform of sequentially captured speckle contrast values over time has characteristics that reflect intracranial blood flow health. If waveform characteristics indicate poor or questionable intracranial blood flow heath, a notification message is displayed, played, or otherwise transmitted.

Abstract: A first optical measurement of tissue with a first optical device is initiated. The first optical measurement includes a first shallow optical reading and a first deeper optical reading. A second optical measurement of the tissue with a second optical device spaced is initiated. The second optical device is spaced apart from the first optical device. The second optical measurement includes a second shallow optical reading and a second deeper optical reading. A first difference value between the first shallow optical reading and the first deeper optical reading is determined. A second difference value between the second shallow optical reading and the second deeper optical reading is determined. A large vessel occlusion (LVO) alert is generated when a ratio of the first difference value to the second difference value is larger than a threshold value.

Abstract: A large vessel occlusion (LVO) alert generated by a point-of-care diagnostic system is received. The LVO alert is representative of a probability of an LVO event in a patient. A mapping coordinate is received. A database of care centers proximate to the mapping coordinate is accessed. A preferred care center from the database is selected based at least on a treatment capability associated with the preferred care center and a distance of the care centers to the mapping coordinate. An LVO event notification is transmitted to initiate stroke medical care.

Abstract: The invention relates to a system and method for isolating particles from a biological fluid, including: obtaining a sample of biological fluid from a source (e.g. a patient) in which the sample contains particles of multiple sample particle types; tagging particles in the sample with tagging agents, including mixing the sample with a solution of magnetic tagging agents that selectively bind to particles of at least one of the sample particle types, thereby forming a group of tagged particles in the sample; passing the sample through a magnetic conduit having a magnetic field that interacts with at least some of the tagged particles; sorting the particles of the sample into multiple groups based on the interaction between the tagged particles and the magnetic field; and optionally returning selected portions of the processed fluid back to its source with or without the addition of appropriate therapeutic agents.

Abstract: The invention relates to a system and method for isolating particles from a biological fluid, including: obtaining a sample of biological fluid from a source (e.g. a patient) in which the sample contains particles of multiple sample particle types; tagging particles in the sample with tagging agents, including mixing the sample with a solution of magnetic tagging agents that selectively bind to particles of at least one of the sample particle types, thereby forming a group of tagged particles in the sample; passing the sample through a magnetic conduit having a magnetic field that interacts with at least some of the tagged particles; sorting the particles of the sample into multiple groups based on the interaction between the tagged particles and the magnetic field; and optionally returning selected portions of the processed fluid back to its source with or without the addition of appropriate therapeutic agents.

Abstract: A microfluidic system for automatically depleting particles not of interest from a biological sample, comprising: a sampling module configured to receive the sample; and one or more microfluidic protein and nucleic acid depletion modules fluidically coupled to the sampling module and comprising binding agents configured to selectively bind to abundant plasma proteins or nucleic acids. A method for automatically depleting particles not of interest from a sample, comprising: receiving the sample; subjecting the sample to a force that separates at least a portion of the particles not of interest from the sample, thereby isolating at least a portion of the target component; passing the isolated target copmonent into a chamber; circulating the isolated target component in the chamber; and selectively capturing proteins or nucleic acids with binding agents within the chamber.

Abstract: The invention relates to a system and method for isolating particles from a biological fluid, including: obtaining a sample of biological fluid from a source (e.g. a patient) in which the sample contains particles of multiple sample particle types; tagging particles in the sample with tagging agents, including mixing the sample with a solution of magnetic tagging agents that selectively bind to particles of at least one of the sample particle types, thereby forming a group of tagged particles in the sample; passing the sample through a magnetic conduit having a magnetic field that interacts with at least some of the tagged particles; sorting the particles of the sample into multiple groups based on the interaction between the tagged particles and the magnetic field; and optionally returning selected portions of the processed fluid back to its source with or without the addition of appropriate therapeutic agents.